SLU-PP-332
Animal studies onlyGet notified when the evidence changes.
Almost all the research is in animals. We do not know if the same thing happens in people.
Compiled and reviewed by the PeptideSearch Editorial Team · Status checked 2026-08-04
A small lab-made chemical, not a peptide. In mice it mimics some effects of exercise. No human studies.
Official status: Not nominated for 503A compounding · Checked 2026-08-04
Can a doctor prescribe this?
- Small pharmacy (503A)
- Never put forward to FDA
- Large outsourcing facility (503B)
- Never put forward to FDA
Research chemical only. Never tested in people and not something a doctor can prescribe.
503A is a pharmacy making a single prescription for one patient. 503B is a facility making batches. They are governed by separate lists. Where a category is shown, it is a position on the FDA's list of substances that have been put forward and are still being worked through — not the final list, which is set by rulemaking. Category 1 means the FDA does not plan to act against a pharmacy that makes it while the review runs.
Lab suppliers we list: 8
Doses used in research
Taken word for word from the studies and trials listed on this page. This is not a recommendation and not a dose for anyone to take.
No dosing information has been published in the research indexed here.
- Animal study, rats or miceAn orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity.
The Journal of pharmacology and experimental therapeutics · 2026
- Animal study, rats or miceA Synthetic ERR Agonist Alleviates Metabolic Syndrome.
The Journal of pharmacology and experimental therapeutics · 2024
- Animal study, rats or miceEstrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney.
The American journal of pathology · 2023
- Animal study, rats or miceA Synthetic ERRα Agonist Induces an Acute Aerobic Exercise Response and Enhances Exercise Capacity
2022
- Animal study, rats or miceNovel ERR pan-agonists ameliorate heart failure through boosting cardiac fatty acid metabolism and mitochondrial function
2022
- Lab dish studyNovel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function.
Circulation · 2024
- Lab dish studySynthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity.
ACS chemical biology · 2023
- Lab test method, not a health studyIn Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential.
Rapid communications in mass spectrometry : RCM · 2026
- Lab test method, not a health studyAnalysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes.
Drug testing and analysis · 2026
- Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study.
Frontiers in physiology · 2025
- Review of earlier workChemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling.
International journal of biological macromolecules · 2026
- Review of earlier work[Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications].
Revista medica de Chile · 2026
Spot an error? corrections@peptidesearch.org